Literature DB >> 9579561

HTLV-1 infection in a population-based cohort of older persons in Guinea-Bissau, West Africa: risk factors and impact on survival.

M Melbye1, A G Poulsen, D Gallo, J B Pedersen, R J Biggar, O Larsen, F Dias, P Aaby.   

Abstract

In 1989, a population-based cohort of persons aged > or = 50 years was established in an urban area of Guinea-Bissau, West Africa. Overall, 346 persons were interviewed in detail about risk behaviors and had capillary blood drawn. Among women, 12.4% were HTLV-1 seropositive, compared with 4.6% in men. No HTLV-2 was found. Seropositivity varied considerably according to place of birth and ethnic group. In women, but not in men, HTLV-1 seropositivity was strongly associated with early sexual debut (10-14 yrs, 33.3%; 15-17 yrs, 26.0%; 18-20 yrs, 6.5%; 21+ yrs, 0%; ptrend = 0.001), lifetime number of male partners (ptrend = 0.006), and the male partner's number of co-wives (ptrend = 0.006). There was also a 3.1-fold increased risk of being HTLV-1 seropositive if the woman was also HIV-2 seropositive. In a multivariate-risk-factor analysis, the strongest association with HTLV-1 was a history of having been bitten by a monkey (n = 11; combined OR adjusted = 10.1; 95% CI 2.3-44.4). Ornamental scarification was associated with a 3.3-fold increased risk. Ethnic affiliation also significantly influenced the risk of being HTLV-1 seropositive. Follow-up performed in January 1996 revealed no difference in survival between HTLV-1-seropositive and -seronegative individuals over 6 years (rate ratio = 1.4, 95% CI 0.7-2.8). In conclusion, this population, which has very high HIV-2 seroprevalence, is also highly endemic for HTLV-1. Whereas sexual behaviors are clearly important for HTLV-1 spread in women, non-sexual risk factors were the only ones of potential importance in men. HTLV-1 had no impact on survival in this older population.

Entities:  

Keywords:  Adult; Africa; Africa South Of The Sahara; Age Factors; Aged; Biology; Demographic Factors; Developing Countries; Diseases; Guinea-bissau; Hiv Infections; Length Of Life; Measurement; Middle Aged; Mortality; Population; Population Characteristics; Population Dynamics; Portuguese Speaking Africa; Prevalence; Research Methodology; Research Report; Risk Factors; Survivorship; Viral Diseases; Western Africa

Mesh:

Year:  1998        PMID: 9579561     DOI: 10.1002/(sici)1097-0215(19980504)76:3<293::aid-ijc1>3.0.co;2-q

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Seroprevalence and molecular epidemiology of human T-Cell leukemia virus type 1 (HTLV-1) and HTLV-2 in blood donors from Dakar, Senegal.

Authors:  Saliou Diop; Sara Calattini; Julienne Abah-Dakou; Doudou Thiam; Lamine Diakhaté; Antoine Gessain
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

Review 2.  Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.

Authors:  Nicolas Legrand; Skye McGregor; Rowena Bull; Sahar Bajis; Braulio Mark Valencia; Amrita Ronnachit; Lloyd Einsiedel; Antoine Gessain; John Kaldor; Marianne Martinello
Journal:  Clin Microbiol Rev       Date:  2022-02-23       Impact factor: 50.129

3.  Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

Authors:  Eduardo Samo Gudo; Nilesh B Bhatt; Dulce Ramalho Bila; Celina Monteiro Abreu; Amílcar Tanuri; Wilson Savino; Suse Dayse Silva-Barbosa; Ilesh V Jani
Journal:  BMC Infect Dis       Date:  2009-12-22       Impact factor: 3.090

4.  HTLV-1 in rural Guinea-Bissau: prevalence, incidence and a continued association with HIV between 1990 and 2007.

Authors:  Carla van Tienen; Maarten F Schim van der Loeff; Ingrid Peterson; Matthew Cotten; Birgitta Holmgren; Sören Andersson; Tim Vincent; Ramu Sarge-Njie; Sarah Rowland-Jones; Assan Jaye; Peter Aaby; Hilton Whittle
Journal:  Retrovirology       Date:  2010-06-04       Impact factor: 4.602

5.  HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community.

Authors:  Carla van Tienen; Maarten Schim van der Loeff; Ingrid Peterson; Matthew Cotten; Sören Andersson; Birgitta Holmgren; Tim Vincent; Thushan de Silva; Sarah Rowland-Jones; Peter Aaby; Hilton Whittle
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

6.  Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran.

Authors:  M R Hedayati-Moghaddam; F Fathimoghadam; I Eftekharzadeh Mashhadi; L Soghandi; H R Bidkhori
Journal:  Iran Red Crescent Med J       Date:  2011-06-01       Impact factor: 0.611

7.  Molecular epidemiology of endemic human T-lymphotropic virus type 1 in a rural community in Guinea-Bissau.

Authors:  Carla van Tienen; Thushan I de Silva; Luiz Carlos Junior Alcantara; Clayton O Onyango; Sheikh Jarju; Nato Gonçalves; Tim Vincent; Peter Aaby; Hilton Whittle; Maarten Schim van der Loeff; Matthew Cotten
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

8.  Relationship Among Strongyloides stercoralis Infection, Human T-Cell Lymphotropic Virus Type 1 Infection, and Cancer: A 24-Year Cohort Inpatient Study in Okinawa, Japan.

Authors:  Teruhisa Tanaka; Tetsuo Hirata; Gretchen Parrott; Miwa Higashiarakawa; Takeshi Kinjo; Tetsu Kinjo; Akira Hokama; Jiro Fujita
Journal:  Am J Trop Med Hyg       Date:  2015-11-30       Impact factor: 2.345

9.  Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau.

Authors:  Birgitta Holmgren; Zacarias da Silva; Pernille Vastrup; Olav Larsen; Sören Andersson; Henrik Ravn; Peter Aaby
Journal:  Retrovirology       Date:  2007-11-27       Impact factor: 4.602

10.  Human T-Lymphotropic Virus type 1 infection in an Indigenous Australian population: epidemiological insights from a hospital-based cohort study.

Authors:  Lloyd Einsiedel; Richard J Woodman; Maria Flynn; Kim Wilson; Olivier Cassar; Antoine Gessain
Journal:  BMC Public Health       Date:  2016-08-15       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.